Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.47 |
| ▸ | GUSB | P08236 | 2/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1252216 | 1.00 | DGAT1 (1.00) | DGAT1CHEK2GUSBSLC2A1PTGDR2 | |
| SCHEMBL1252747 | 0.92 | DGAT1 (0.85) | DGAT1CHEK2GUSBSLC2A1 | |
| SCHEMBL1252030 | 0.91 | DGAT1 (0.83) | DGAT1CHEK2 | |
| SCHEMBL31326547 | 0.91 | DGAT1 (0.83) | DGAT1CHEK2 | |
| SCHEMBL10299677 | 0.91 | DGAT1 (0.83) | DGAT1CHEK2GUSB | |
| SCHEMBL1250496 | 0.89 | DGAT1 (0.80) | DGAT1CHEK2GUSB | |
| SCHEMBL25216331 | 0.88 | DGAT1 (0.78) | DGAT1GUSBSLC2A1 | |
| SCHEMBL21354092 | 0.86 | DGAT1 (1.00) | DGAT1CHEK2GUSBSLC2A1PTGDR2 | |
| SCHEMBL30565806 | 0.86 | DGAT1 (1.00) | DGAT1CHEK2GUSBSLC2A1PTGDR2 | |
| SCHEMBL1252194 | 0.86 | DGAT1 (0.75) | DGAT1CHEK2GUSBSLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166204-B | Cyclic peptides as inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-113166114-B | Cyclic tetramer compounds as inhibitors of proprotein convertase subtilisin/KEXIN type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2023084449-A1 | DIAMINOCYCLOPENTYLPYRIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2023-05-19 | — | — | WO | disclosed |